Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Signs Drug-Development Agreement, One Step Closer to Effective Psychiatric Disorder Treatment
Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disorders Cybin looking to identify fast-acting, shorter-duration formulations of CYB003 Delivering CYB003 through Catalent ODT could provide significant benefits Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products (https://ibn.fm/nQdpg). The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially…